U.S. Markets open in 9 hrs 4 mins

CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin

This Additional Production Will Ensure Availability Through the Completion of its Upcoming Phase II Clinical Trials

HOUSTON, Jan. 14, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has signed a contract with NCK A/S for the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.

NCK A/S is a GMP manufacturer of complex drugs located in Farum, Denmark, and the previous producer of Berubicin for Reata Pharmaceuticals. Production of large scale Berubicin is set to commence in January and will ensure drug availability through the end of Phase II clinical trials for glioblastoma.

"We are extremely excited to have entered into a contract with NCK A/S. We believe working with an experienced company in the production of this class of anthracyclines is paramount given the complex chemistry and difficulty to produce very high purity for human use," stated John Climaco, CEO of CNS Pharmaceuticals. "We are confident in NCK A/S' ability to succeed in the large scale production of our lead candidate due to its extensive experience in Berubicin synthesis for previous clinical trials. This contract represents a key stride in the development of Berubicin and secures drug availability as we look forward not only to initiate but also expand Phase II clinical trials later this year."

About Berubicin
Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents.  Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation.  Berubicin was developed at the MD Anderson Cancer Center (MDACC), which is the top ranked cancer center in the US, and largest cancer research and treatment facility in the world.  Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata. 

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors.  Its lead candidate Berubicin is proposed for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as for pancreatic and ovarian cancers, and lymphomas.  The Company entered into an intellectual property (IP) agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata.  For more information, visit www.cnspharma.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Company to prepare its IND and to commence its upcoming potential Phase II study. These statements relate to future events, future expectations, plans and prospects. Although CNS believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Risk Factors" in the Form S-1 we filed with the SEC on October 7, 2019. Any forward-looking statements contained in this release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

Cision

View original content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-contract-with-international-gmp-manufacturer-for-production-of-berubicin-300986285.html

SOURCE CNS Pharmaceuticals, Inc.

  • Elon Musk Calls Bill Gates Underwhelming After Billionaire Buys a Porsche
    Business
    Bloomberg

    Elon Musk Calls Bill Gates Underwhelming After Billionaire Buys a Porsche

    If he was expecting kind words in return from Elon Musk, he apparently shouldn't have spoken about challenges that still lie ahead -- or about his new Porsche. Gates, the billionaire co-founder of Microsoft Corp., spoke with a YouTube influencer last week about the challenges of reducing emissions to slow climate change. “And certainly Tesla, if you had to name one company that's helped drive that, it's them,” Gates told YouTuber Marques Brownlee.

  • Billionaire Ray Dalio Pulls the Trigger on 3 “Strong Buy” Stocks
    Business
    TipRanks

    Billionaire Ray Dalio Pulls the Trigger on 3 “Strong Buy” Stocks

    On top of this, he pointed out, “Debunking 'too big to grow fears,' BLK delivered 7%-plus organic asset growth for the full year 2019, which is an acceleration from 2.1%-plus organic growth in 2018 and 4.3%-plus average growth rate over last five years. Importantly, strong net new money growth translated into 5% organic base fee growth in 2019, better than the 2% growth in 2018. Based on this report, Cyprys expects other analysts to make adjustments to their outlooks for 2020.

  • The hedge-fund investor who has beaten Warren Buffett by 200x likely made a killing on Tesla
    Business
    MarketWatch

    The hedge-fund investor who has beaten Warren Buffett by 200x likely made a killing on Tesla

    Renaissance Technologies, added more than 3 million shares of Tesla to its holdings in the fourth quarter of last year, as the electric-vehicle maker's shares catapulted higher, according to public filings. The hedge fund founded by James Simons, considered the premiere quantitative-driven investor, owned 3.9 million shares of Tesla at the end of Dec. 31, with the company's stake in Renaissance's portfolio jumping from 0.1% in the prior quarterly period to 1.3%, according to file-tracking site Whalewisdom. The purchases would have come as Tesla's shares (TSLA) were zooming higher, punishing a number of investors with short positions who had bet that the Elon Musk-run Silicon Valley darling would see its price collapse soon.

  • The Wuhan Virus and Research-Focused Biotech Companies
    Business
    GuruFocus.com

    The Wuhan Virus and Research-Focused Biotech Companies

    The problem with these companies is that their low or nonexistent revenues result in a weak investor perception as the qualitative benefits of their research cannot be measured tangibly. However, with the outbreak of the Wuhan coronavirus, the importance of investing in the research of such companies is suddenly a hot topic in the investor community, which is why many of these stocks have seen their prices rise. Warning!

  • 10 Stocks' Profit Will Soar More Than Anyone Dreamed, Analysts Say
    Business
    Investor's Business Daily

    10 Stocks' Profit Will Soar More Than Anyone Dreamed, Analysts Say

    Analysts' forecast for S&P 500 profit for 2020 has declined all year, says FactSet. Digging further shows you just how much. Analysts Souring On S&P 500 Earnings Most S&P 500 companies are expected to make less than thought in 2020, not more.

  • Bloomberg's new plan to crack down on Wall Street includes a financial transaction tax
    Politics
    Yahoo Finance

    Bloomberg's new plan to crack down on Wall Street includes a financial transaction tax

    Bloomberg has been campaigning as a more moderate alternative to candidates like Sen. Elizabeth Warren (D-MA) and Sen. Bernie Sanders (I-VT) and has been courting business leaders and Wall Street executives — who will likely cringe at the idea of a financial transaction tax. But the more progressive wing of the party has championed even tougher regulations and taxes on Wall Street on the wealthiest Americans. Bloomberg's financial transaction tax would be phased in gradually, starting at 0.02% to “monitor and minimize unintended consequences.

  • InMode Reverses Lower
    Business
    Investor's Business Daily Video

    InMode Reverses Lower

    InMode reported strong earnings, sales and guidance … but after surging at the open shares reversed lower. Has a 53.30 cup-with-handle buy point. Looked like an early entry at the open – but good idea to wait 5 minutes or even for topping first-hour high, especially with a volatile IPO like INMD.

  • Walmart expects to save $60 million annually on shopping bags
    Business
    MarketWatch

    Walmart expects to save $60 million annually on shopping bags

    Walmart Inc. is saving big bucks on an unexpected part of the business: shopping bags. The world's largest company by revenue expects to save $60 million annually on plastic shopping bags, “just by changing our buying process and better utilizing our scale,” Chief Financial Officer Brett Biggs said. The remarks were made after the retail giant announced its fourth-quarter earnings on Tuesday.

  • Michael Burry's Scion Asset Management Buys 5 Stocks in the 4th Quarter
    Business
    GuruFocus.com

    Michael Burry's Scion Asset Management Buys 5 Stocks in the 4th Quarter

    GuruFocus has detected 5 Warning Signs with BBBY. Click here to check it out. BBBY 30-Year Financial Data The intrinsic value of BBBY Peter Lynch Chart of BBBY As of quarter-end, Scion's $82 million equity portfolio contains nine stocks, with turnover of 48%.

  • Business
    TheStreet.com

    How Much Do Doctors Make?

    Doctors adhere to the Hippocratic Oath, which stems from Greek medical history, and calls for physicians to swear to uphold the highest ethical standards in the service of medicine. The numbers do vary for the average physician salary, depending on the source of the information. Data from ZipRecruiter notes the average annual pay for a "medical doctor" stands at $224,190 in 2018, with the highest salaries in the $397,000 range and on the lower end at $23,500.

  • Leon Cooperman's Top 6 Buys for the 4th Quarter
    Business
    GuruFocus.com

    Leon Cooperman's Top 6 Buys for the 4th Quarter

    GuruFocus ranks Ferro's profitability 7 out of 10: operating margins have expanded over the past five years despite outperforming just 57.46% of global competitors. Additionally, Ferro's three-year revenue growth rate of 15.90% outperforms 77.69% of global chemical companies. Mario Gabelli (Trades, Portfolio) also has a holding in Ferro.

  • Boeing finds debris in 737 MAX jetliners - company memo
    Business
    Reuters

    Boeing finds debris in 737 MAX jetliners - company memo

    Boeing Co found debris that could pose potential safety risks in the fuel tanks of several 737 MAX aircraft that are in storage and waiting to be delivered to airlines, according to an internal memo seen by Reuters on Tuesday. Foreign object debris, an industrial term for rags, tools, metal shavings and other materials left behind by workers during the production process, has been a quality control issue for various Boeing aircraft, such as its KC-46 tankers. Mark Jenks, general manager of the 737 programme, told employees in the memo that such debris was "absolutely unacceptable" and that the company was taking steps to address the issue in its production system.

  • Dow Jones Futures: AMD Ignores Apple-Led Retreat; Enphase, SolarEdge, Amedisys, 10X Genomics, Palomar Are Key Movers
    Business
    Investor's Business Daily

    Dow Jones Futures: AMD Ignores Apple-Led Retreat; Enphase, SolarEdge, Amedisys, 10X Genomics, Palomar Are Key Movers

    Dow Jones futures rose modestly Tuesday, along with S&P 500 futures and Nasdaq futures. The stock market rally held up well Tuesday despite an Apple revenue warning on the coronavirus. Enphase Energy, Amedisys and 2019 IPO stocks 10X Genomics and Palomar Holdings reported earnings.

  • Roku, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates
    Business
    Simply Wall St.

    Roku, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates

    The yearly results for Roku, Inc. (NASDAQ:ROKU) were released last week, making it a good time to revisit its performance. Following the result, analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Following the latest results, Roku's 15 analysts are now forecasting revenues of US$1.61b in 2020.

  • Business
    GuruFocus.com

    SpaceX: Starlink IPO Should See Hope Trump Economics

    GuruFocus has detected 8 Warning Signs with IRDM. Click here to check it out. IRDM 30-Year Financial Data The intrinsic value of IRDM Peter Lynch Chart of IRDM An expensive endeavor Musk made Starlink the key pillar of his pitch to investors during SpaceX's most recent funding round, espousing his belief that it will be the profit engine that will drive the company's more ambitious, but less lucrative, pursuits.

  • Business
    Barrons.com

    Tesla Stock Is Still Skyrocketing. Critics Are Giving Up.

    Investors who thought (TSLA) stock's volatility would calm down after its epic stock price rise are, apparently, wrong. Tesla (ticker: TSLA) stock was up more than 7% in trading on Tuesday, to about $858.40 a share at the close, after three bearish Wall Street analysts increased their price targets. None, however, upgraded the stock.

  • Netflix Stock Is Nearing A Key Buy Point
    Business
    Investor's Business Daily Video

    Netflix Stock Is Nearing A Key Buy Point

    The IBD Live Team discusses Netflix stock on Tuesday as it nears a key cup-based buy point.

  • Chinese Companies Say They Can’t Afford to Pay Workers Right Now
    Business
    Bloomberg

    Chinese Companies Say They Can’t Afford to Pay Workers Right Now

    With classes canceled at a coding-and-robotics school in Hangzhou, employees will lose 30% to 50% of their wages. The Lionsgate Entertainment World theme park in Zhuhai is closed, and workers have been told to use up their paid vacation time and get ready for unpaid leave.“A week of unpaid leave is very painful,” said Jason Lam, 32, who was furloughed from his job as a chef in a high-end restaurant in Hong Kong's Tsim Sha Tsui neighborhood. Across China, companies are telling workers that there's no money for them -- or that they shouldn't have to pay full salaries to quarantined employees who don't come to work.

  • If you could buy only one stock for 5G and artificial intelligence exposure, this would be it
    Business
    MarketWatch

    If you could buy only one stock for 5G and artificial intelligence exposure, this would be it

    During the California gold rush, many miners went bankrupt. Most investors recognize that the gold rush is on in 5G and artificial intelligence. The picks and shovels for the present-day gold rushes are semiconductors.

  • Booming market for influencers to hit $15 billion: analyst
    Business
    Yahoo Finance

    Booming market for influencers to hit $15 billion: analyst

    Social media influencers are everywhere, and they aren't likely to go away anytime soon, said Sylvia Jablonski, managing director of capital markets at Direxion. Influencers haven't just changed how people shop — they've completely transformed the advertising industry landscape. "I think influencers are staked to become very, very rich," she said, noting that the spend on influencers is going to go from about $8 billion today to about $15 billion in the next couple of years.

  • Here’s the reason Americans are saving so much of their income
    Business
    MarketWatch

    Here’s the reason Americans are saving so much of their income

    U.S. household wealth compared to income is near a record high. In the fourth quarter, savings as a percent of disposable income was 7.7%, more or less the post-crisis average. Some of the explanation can be boiled down to: Goldman's clients.

  • David Rolfe Adds 4 Stocks to Portfolio in 4th Quarter
    Business
    GuruFocus.com

    David Rolfe Adds 4 Stocks to Portfolio in 4th Quarter

    The stock traded for an average price of $57.47 per share during the quarter. The New York-based pharmaceutical company, which focuses on drugs to treat cardiovascular, oncology and immune disorders, has a $155.61 billion market cap; its shares were trading around $66.38 on Tuesday with a price-earnings ratio of 30.25, a price-book ratio of 6.11 and a price-sales ratio of 4.48. The Peter Lynch chart shows the stock is trading above its fair value, suggesting it is overpriced.

  • Twitter Buys Chroma Labs, Startup Founded by Facebook Veterans
    Business
    Bloomberg

    Twitter Buys Chroma Labs, Startup Founded by Facebook Veterans

    Chroma Labs was launched last fall with an app that lets people edit photos and videos before sharing them on the Stories features inside other apps, like Instagram or Snap Inc.'s Snapchat. The company is joining Twitter to “give people more creative ways to express themselves in conversations,” said Twitter's head of product, Kayvon Beykpour, in a tweet.

  • 3 “Strong Buy” Stocks Top Investors Are Snapping Up Right Now
    Business
    TipRanks

    3 “Strong Buy” Stocks Top Investors Are Snapping Up Right Now

    See Centene stock analysis on TipRanks) Applied Materials (AMAT) Next up is a fellow large cap, though from an entirely different sector. Semi-conductor company Applied Materials makes integrated circuit chips for a wide range of electronics, including TVs, smartphones and flat panel display screens. The $61 billion heavyweight's robust start to 2020 is a direct continuation of 2019's stellar performance; last year's gains of 90% have been boosted by a further 9% year-to-date.

  • What ‘Rothifying’ 401(k)s Would Mean for Retirees
    Business
    The Wall Street Journal

    What ‘Rothifying’ 401(k)s Would Mean for Retirees

    Research shows that switching 401(k)s to after-tax contributions would boost tax returns in the short term, but leave retirees worse off.